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Abstract
Cystic fibrosis (CF) is caused by mutations in the gene encoding the epithelial chloride chan-
nel CF transmembrane conductance regulator (CFTR) protein. The most common mutation
is a deletion of three nucleotides leading to the loss of phenylalanine at position 508 (p.
Phe508del) in the protein. This study evaluates eluforsen, a novel, single-stranded, 33-
nucleotide antisense oligonucleotide designed to restore CFTR function, in in vitro and in
vivo models of p.Phe508del CF. The aims of the study were to demonstrate cellular uptake
of eluforsen, and its efficacy in functional restoration of p.Phe508del-CFTR both in vitro and
in vivo. In vitro, the effect of eluforsen was investigated in human CF pancreatic adenocarci-
noma cells and human bronchial epithelial cells. Two mouse models were used to evaluate
eluforsen in vivo. In vitro, eluforsen improved chloride efflux in CF pancreatic adenocarci-
noma cell cultures and increased short-circuit current in primary human bronchial epithelial
cells, both indicating restoration of CFTR function. In vivo, eluforsen was taken up by airway
epithelium following oro-tracheal administration in mice, resulting in systemic exposure of
eluforsen. In female F508del-CFTR mice, eluforsen significantly increased CFTR-mediated
saliva secretion (used as a measure of CFTR function, equivalent to the sweat test in
humans). Similarly, intranasal administration of eluforsen significantly improved nasal
potential difference (NPD), and therefore CFTR conductance, in two CF mouse models.
These findings indicate that eluforsen improved CFTR function in cell and animal models of
p.Phe508del-CFTR-mediated CF and supported further development of eluforsen in human
clinical trials, where eluforsen has also been shown to improve CFTR activity as measured
by NPD.
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Introduction
Cystic fibrosis (CF) is a genetic disorder that affects the respiratory, digestive, and reproductive
organs, and has a varied world-wide prevalence, with an estimated 1 in 2,000–3,000 newborns
affected by CF in Europe and 1 in 3,500 newborns affected by CF in the USA [1]. Individuals
with this progressive condition typically experience multisystem organ failure and ultimately
premature death, with a median age at death of 27 years [2]. More specifically, CF is an autoso-
mal recessive disease caused by mutations in the gene encoding the CF transmembrane con-
ductance regulator (CFTR) protein [3]. CFTR is an anion channel present mainly in the apical
membrane of epithelial cells, where it regulates fluid and electrolyte transport across the epi-
thelium [4]. Therefore, a loss of CFTR function causes dehydration and acidification of the
apical epithelial surface and a subsequent buildup of thick mucus, which can lead to fatal lung
infections [5,6], as well as pancreatic insufficiency and poor absorption of nutrients [1].
To date, over 2,000 mutations of CFTR have been identified [7], which correspond to vary-
ing degrees of loss of CFTR function, and a spectrum of clinical presentations of CF [8]. The
most common CFTR mutation is a deletion of three nucleotides in the DNA leading to the
loss of a phenylalanine at position 508 (p.Phe508del) in the protein, which accounts for
approximately 70% of mutated alleles in patients of European descent with CF [8,9]. The p.
Phe508del mutation impairs proper biosynthesis of the CFTR protein, which is misfolded and
targeted for proteosomal degradation. Furthermore, p.Phe508del-CFTR that does reach the
cell surface has a reduced half-life due to increased endocytosis. Moreover, p.Phe508del-CFTR
shows defects in channel gating and thermostability, and is therefore difficult to repair at the
protein level [10,11].
Before the CFTR gene was first described in 1989 [3], CF therapies managed symptoms but
did not address the underlying cause of the disease. The goal for CF therapeutic development
has since shifted to restoration of functional CFTR, and to that end two main approaches have
been explored to date: gene therapy and small molecules targeting the mutated protein. Gene
therapy, aiming to permanently introduce wild-type (WT) CFTR, has so far demonstrated
only minimal success in CF [12,13]. In contrast, several small molecules have been shown to
improve CFTR protein function, as exemplified by the FDA-approved CFTR potentiator iva-
caftor, which is used as monotherapy or in combination with the CFTR corrector lumacaftor
[14–16]. However, while small molecule approaches have recently demonstrated robust thera-
peutic effects in patients with CF with specific CFTR mutations [17,18], there remains an
unmet clinical need for patients with the p.Phe508del mutation.
The use of antisense oligonucleotides to modulate p.Phe508del-CFTR mRNA has already
shown some therapeutic potential [19,20]. In 2004, Zamecnik et al. [21] demonstrated that
treatment of a cultured p.Phe508del-CFTR cell line with a duplex consisting of a 33-nucleotide
(nt) 2’-O-methyl-modified RNA oligonucleotide 100% homologous to WT CFTR mRNA, and
an 11 nt RNA oligonucleotide (respectively termed CF4 and CF6), restored CFTR function
[21]. Since it was not shown that both oligonucleotides in the duplex were essential for reversal
of phenotype, we designed an improved version of CF4 alone, previously designated as QR-
010, and now known as eluforsen (the International Non-Proprietary Name, eluforsen, is cur-
rently under review).
The aims of the present study were to demonstrate cellular uptake of eluforsen, and its effi-
cacy in functional restoration of p.Phe508del-CFTR both in vitro and in vivo. Endpoints were
selected to maximize translational relevance, and included the saliva secretion assay, which is
equivalent to the sweat test endpoint used in clinical trials, and nasal potential difference
(NPD), which is used to diagnose CF and is a common endpoint in clinical trials of CF thera-
pies [16,22–24].
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Materials and methods
Eluforsen and control oligonucleotides
Eluforsen is a 33 nt, single-stranded, fully phosphorothioated and fully 2’-O-methyl-modified
oligonucleotide partly complementary to the p.Phe508del-CFTR RNA, and based on the CF4
molecule (5’-AUCAUAGGAAACACCAAAGAUGAUAUUUUCUUU-3’) [21]. Eluforsen was
manufactured via a solid-phase synthesis followed by a chromatographic purification step, and
then freeze-dried to give eluforsen as a lyophilized white to off-white solid. Phosphorothioate
modifications to oligonucleotides have been previously demonstrated to protect against break-
down by nucleases and improve cellular uptake [25], therefore eluforsen was designed as a
fully phosphorothioated variant of CF4. The Cy5-labeled eluforsen used in our studies con-
tained a Cy5 label covalently bound to the 5’ end of eluforsen. A scrambled control oligonucle-
otide (5’-UAUUCAAGUUACACUCAAGAAGGAAUAAUUUCU-3’) with the same chemical
modifications as eluforsen was used as a negative control.
For in vitro experiments, 100 μM or 1 mM stock solutions of eluforsen, the control oligonu-
cleotide (both from Biospring, Frankfurt, Germany), and Cy5-labeled eluforsen (Axo Labs,
Kulmbach, Germany) were prepared by dissolving each oligonucleotide in sterile water (Ver-
sol, Aguettant, Lyon, France), resulting in an isotonic, isoosmolar solution. For the in vivo
saliva secretion assays, 5 mg/mL stock solutions (Nitto Denko Avecia, Milford, MA, USA)
were prepared by dissolving eluforsen in sterile saline (0.9% NaCl in water). For the in vivo
NPD experiments, 20 mg/mL stock solutions (Biospring) were prepared by dissolving elufor-
sen in sterile saline.
Cell cultures
Human CF pancreatic adenocarcinoma (CFPAC-1) cells were used to assess the effect of elu-
forsen on CFTR function. Cells were obtained from the American Type Culture Collection
(CRL-1918; Manassas, VA, USA) and cultured according to the manufacturer’s instructions
[26]. To test eluforsen in CFPAC-1 cells, these cells were transfected using Lipofectamine 2000
(Life Technologies), as this results in rapid delivery of antisense oligonucleotides to these cells.
Eluforsen was also tested in primary human bronchial epithelial (HBE) cells from homozygous
p.Phe508del CF donors (Asterand, Royston, UK). HBE cells were seeded at a density of
1.67 × 104 cells/plate in cell culture plates (Ø 100 mm, VWR, Amsterdam, the Netherlands)
and cultured in keratinocyte serum-free medium supplemented with 0.2 ng/mL epidermal
growth factor 1–53, 25 μg/mL bovine pituitary extract, 1% penicillin/streptomycin (all from
Life Technologies, Bleiswijk, the Netherlands), and 1 μM isoproterenol-HCl (Sigma Aldrich,
Zwijndrecht, the Netherlands), until approximately 80%–90% confluent.
Differentiation of HBE cells was achieved using air–liquid interface (ALI) culture (further
details can be found in the supporting information, S1 File). Alternatively, HBE cell cultures
from a homozygous p.Phe508del CF donor (Epithelix Sàrl, Plan-Les-Ouates, Switzerland)
were supplied as fully differentiated epithelium grown on permeable supports at ALI and
grown in MucilAir medium (Epithelix Sàrl). To ensure that the HBE cells were fully differenti-
ated, the cells were cultured for at least 3 weeks in ALI before the start of treatment.
As opposed to the transfection method used for CFPAC-1 cells, due to difficulties with
transfection of eluforsen into differentiated HBE cells (consistent with previous reports
[27,28]), continued exposure of the cells to a medium containing Cy5-labeled eluforsen, with-
out transfection reagent, was employed. This technique resulted in a gradual gymnotic uptake
of oligonucleotide over time. Cultures were treated with either eluforsen, fluorescent Cy5-la-
beled eluforsen, or scrambled control oligonucleotide by adding the test compound to the
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culture medium at final concentrations ranging from 1 nM to 30 μM. This method of adminis-
tration to HBE cultures was used for both the Ussing chamber experiments and the micro-
scopic analysis of eluforsen uptake.
In vitro analysis of eluforsen uptake
In order to assess uptake of eluforsen by HBE cells, eluforsen was labeled with Cy5 and admin-
istered to primary HBE cultures. HBE cultures were treated from 2 to 28 days with fluores-
cently labeled eluforsen. After treatment, the cultures were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS; Life Technologies) and permeabilised with 0.1% Triton X-100
(Promega, Leiden, the Netherlands) in PBS. Next, the cultures were blocked with PBS + 5%
bovine serum albumin (Sigma Aldrich), then incubated with Alexa Fluor 488-labeled phalloi-
din (1:40 in PBS + 5% bovine serum albumin, Life Technologies) to stain for F-actin, and sub-
sequently washed four times with PBS. Hoechst nuclear staining (NucBlue Live ReadyProbes
Reagent, Life Technologies) was added to visualize the nucleus. The uptake of Cy5-labeled elu-
forsen was assessed using an Axio Observer confocal microscope with a Zeiss laser scanning
microscope exciter (Zeiss, Sliedrecht, the Netherlands). Pictures were processed using ZEN
black software (Zeiss).
In vitro assessment of eluforsen-mediated restoration of CFTR function:
Chloride efflux assay
Chloride efflux from CFPAC-1 cells was assessed using the halide-sensitive fluorescent indica-
tor N-(6-methoxyquinolyl) acetoethyl ester (MQAE; Life Technologies), as has previously
been described [29]. CFPAC-1 cells were seeded at a density of 1.5 × 104 or 1.3 × 105 cells/cm2
in a black clear-bottom 96-well plate (μClear, 655096, Greiner Bio-One, Alphen aan den Rijn,
the Netherlands) and incubated overnight. Next, cells were transfected with 100 nM eluforsen
or control oligonucleotide using Lipofectamine 2000 (Life Technologies) (further details can
be found in the supporting information, S1 File). The MQAE assay was then performed on
these cells. Briefly, cells were incubated in chloride buffer for 15 minutes before being placed
in low chloride buffer containing forskolin (Reagent Direct, Encinitas, CA, USA) and 10 μM
VX-770 (CFTR potentiator; Selleck Chemicals, Munich, Germany), and the fluorescent signal
of MQAE quenching was measured over 2 minutes as a measure of CFTR-mediated chloride
efflux (further details can be found in the supporting information, S1 File).
In vitro assessment of eluforsen-mediated restoration of CFTR function:
Ussing chamber assay
In brief, HBE cells were transferred to Ussing chambers with chloride buffer added to the
basolateral and the apical side of the cells (further details can be found in the supporting infor-
mation, S1 File). The difference in CFTR-specific current with eluforsen or scrambled control
was measured by adding amiloride to block the predominant sodium channel and testing the
difference in short-circuit current (Isc) with maximum CFTR activation (by isoproterenol and
potentiator [VX-770 or genistein (Sigma Aldrich)]) and CFTR inhibition (by CFTRinh-172
[Sigma Aldrich]).
Mice
Young adult (12–16 weeks old, males and females, 20–30 g) mice homozygous for the p.
Phe508del-CFTR mutation (F508del-CFTR mice), representative of the mutation found in
patients with CF, were ordered from Bayer Wuppertal (congenic FVB Cftrtm1EUR [30,31], for
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saliva secretion assay), bred at the University of Louvain (mixed background 129/FVB
Cftrtm1EUR [30,31], for NPD initial experiments), or ordered from The Jackson Laboratory
(congenic B6.129S6-Cftrtm1Kth/J [32], for further NPD experiments). For biodistribution stud-
ies only, C57BL/6 (WT) mice and BALB/c nu/nu (nude) mice (both from Charles River Labo-
ratories, Sulzfeld, Germany) were used. Nude mice were used to allow in vivo imaging of
IRDye800-labeled eluforsen, as mouse hairs interfere with fluorescent imaging. For all animal
studies, treatment groups were divided over several study cohorts to ensure that measurements
were performed throughout the day. Other than equal proportioning of mice of different ages
and gender to each treatment group, all animal studies were randomized and analysis of data
was blinded. Sample sizes were estimated based on in vitro data, or limited by the available
number of animals. Mice were group-housed under specific pathogen-free conditions with
reversed light–dark cycle and cage enrichment according to recommendations of the Federa-
tion of European Laboratory Animal Science Associations. F508del-CFTR mice were fed with
specialized high-protein chow (SM AB diets Breeding, Ssniff Spezialdia¨ten GmbH, Soest, Ger-
many) to prevent intestinal obstruction. Water and food were supplied ad libitum. Animal
experiments were approved by the local Ethics Committee and conformed to the European
Community regulations (CEE n˚ 86/609). The local Ethics Committee was the local animal
welfare body of Innoser Laboratories BV (Leiden, the Netherlands) and the project license was
granted by the Dutch Central Authority for Scientific Procedures on Animals (CDD).
Lung administration of eluforsen
For salivary secretion experiments, FVB Cftrtmi1EUR mice (female n = 9, male n = 10) were
dosed with eluforsen via oro-tracheal (OT) administration to effectively mimic inhalation,
every other day (EOD) up to six doses [33]. Saline was chosen as the in vivo control (female
n = 9, male n = 8) due to the unknown safety profile of a scrambled oligonucleotide, and also
to correlate with placebo-controlled human clinical trials in which saline would act as the pla-
cebo. Mice were anesthetized with a 2.5% isoflurane/2% oxygen and air mixture for at least 3
minutes. The mice were then hung from their front teeth on a plastic line of the mouse intuba-
tion platform (model MIP, Penn-Century, Wyndmoor, PA, USA). The nose was blocked
using one finger, to prevent nasal breathing, and the tongue was fixed in a protruded position
using forceps. A total of 50 μL of formulated eluforsen in saline (5 mg/mL), or saline alone,
was administered into the throat using a micropipette. The nose was kept blocked for an addi-
tional 20 seconds to allow the test item to be taken up by the lung.
In vivo imaging and post-mortem detection of eluforsen biodistribution
For in vivo imaging, nude mice were sedated with 2%–3% isoflurane/air mixture and imaged
with the Pearl Impulse Small Animal Imaging System (LI-COR Biosciences, Leusden, The
Netherlands) at 0 and 15 minutes; 1, 3, 6, 24, 48, 72, and 96 hours; and 7 days after OT dosing
of IRDye800-labeled eluforsen (n = 3), IRDye800 dye (n = 1), and unlabeled eluforsen (n = 1).
Images were acquired at 800 nm. The fluorescent signal was digitized and electronically dis-
played as a pseudo-color overlay on a gray-scale white light image of the animal. The data were
analyzed using Pearl Impulse Software, version 2.0 (LI-COR Biosciences). For post-mortem
detection, nude mice were killed 7 days after OT administration by CO2 asphyxiation. Blood
was drawn and organs (lung, kidney, trachea, heart, liver, spleen, pancreas, duodenum, and
ilium) were removed, snap frozen, and stored at –80˚C. Fluorescent signal of IRDye800 in
whole organs was detected using an ODYSSEY CLx imaging system (LI-COR Biosciences)
and images were acquired.
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Preparation of mouse lung tissue for confocal microscopy detection of
Cy5-labeled eluforsen
WT mice (n = 3 per time point; six time points) were killed under anesthesia (2%–3% isoflur-
ane/air mixture) by intra-cardiac puncture. Lungs were filled via the trachea with 0.7 mL 4%
paraformaldehyde and incubated overnight. After washing with ethanol and xylol, the tissues
were embedded in paraffin overnight. Next, 10 μm sections were cut and deparaffinized.
Finally, a drop of 4’,6-diamidino-2-phenylindole (Vector Labs, Amsterdam, the Netherlands)
was added to stain the nuclei. Slides were analyzed on a laser scanning microscope observer
with Zen Black software (Zeiss).
Hybridization high-performance liquid chromatography for detection of
Cy5
In short, complete lungs of WT mice (n = 3 per time point; six time points) were disrupted
using a freezer mill, and lysates prepared with an ultrasonic stick in the presence of tissue and
cell lysis solution containing proteinase K (Epicentre, Madison, WI, USA). Cy5-labeled elufor-
sen was detected using anion-exchange high-performance liquid chromatography (HPLC)
with fluorescent detection. A specific fluorescently labeled probe (Atto425-labeled peptide
nucleic acid probe, Panagene, Daejeon, Korea) homologous to eluforsen was used to capture
eluforsen in serum or tissue lysates, and absolute concentrations were determined by quantita-
tive HPLC measurements using a Shimadzu Fluorescence Detector 20Axs (Shimadzu Corpo-
ration, Kyoto, Japan; λexcitation 437 nm; λemission 483 nm).
In situ hybridization for detection of eluforsen in tissue
The RNAscope 2.0 FFPE Detection Kit (Advanced Cell Diagnostics, Hayward, CA, USA),
using customized optimized detection probes complementary to eluforsen, was used to visual-
ize eluforsen in lung tissue.
In vivo assessment of eluforsen-mediated restoration of CFTR function:
Saliva secretion assay in F508del-CFTR mice
Total CFTR-mediated saliva secretion was assessed before treatment and after OT administra-
tion of one to six doses of eluforsen (10 mg/kg) or saline. The saliva secretion assay was per-
formed in eluforsen- or saline-treated FVB Cftrtmi1EUR F508del-CFTR mice according to a
modified version of the method developed by Best et al. [34]. Briefly, mice were anesthetized
by isoflurane, then received a subcutaneous injection with atropine sulfate (50 μL, 1 mM in
saline, Sigma Aldrich) in the left cheek. A cotton bud was used to absorb any remaining saliva
from the left and right cheeks. At time 0, a mixture (100 μL) of atropine sulfate (1 mM) and
isoproterenol (100 μM, Sigma Aldrich) in saline was injected subcutaneously in the left cheek
to induce CFTR-mediated saliva production. Subsequently, every 3 minutes for the next 30
minutes, dry, pre-weighed filter paper was positioned in the cheek of the mouse to absorb
saliva. The amount of CFTR-mediated saliva secreted was determined by weighing these 10 fil-
ter papers and subtracting the dry weight from the total, and then corrected for body weight.
Mice were dosed with eluforsen (10 mg/kg; n = 19) or saline (n = 17) by OT administration
EOD. The saliva secretion assay was performed 1–7 days pre-treatment (baseline), and 24
hours after receiving one, two, four, and six doses of eluforsen.
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In vivo assessment of eluforsen-mediated restoration of CFTR function:
NPD in F508del-CFTR mice
Initial NPD measurements were recorded in fully anesthetized eluforsen-treated F508del-
CFTR (FVB/129 Cftrtm1EUR) mice (n = 18) or untreated WT littermates (n = 6). Further NPD
analyses were carried out in B6.129S6-Cftrtm1Kth/J mice treated with eluforsen (n = 10), scram-
bled control (n = 10), and saline (n = 9). Mice were age-matched per treatment group and an
equal ratio of male and female mice were used for these studies. Measurements were carried
out as previously described [35]. The baseline (pre-treatment) NPD was measured using iso-
tonic saline Ringer’s solution until a stable value was obtained. Subsequently, a series of solu-
tions were sequentially perfused to assess the nasal ion flow:
1. Amiloride was added to the isotonic saline Ringer’s solution (NaCl [140 mM], CaCl2.2H2O
[2.0 mM], MgCl2.6H2O [1.0 mM], KCl [6.0], d-Glucose [10 mM], HEPES [10 mM]) to
assess the transepithelial potential (VTE) amiloride.
2. A chloride-free buffer (NaC6H11O7 [140 mM], C12H22CaO14 [6 mM], MgCl2.6H2O [1.0
mM], C6H11KO7 [6 mM], d-Glucose [10 mM], HEPES [10 mM]) containing amiloride (0.1
mM) was added to assess the VTE zero Cl-.
3. A chloride-free buffer (same composition as above) containing amiloride (0.1 mM) and for-
skolin (10 μM) was added to assess the VTE forskolin.
The total CFTR-mediated Cl− conductance was defined as the total change in VTE (ΔVTE
total-Cl�) after sequential perfusion with the zero Cl
− and forskolin-containing buffers relative to
the potential difference after perfusion with the ringer solution containing amiloride. In initial
NPD experiments, mice received eluforsen (2 μL, 40 μg/dose) EOD via intranasal (IN) admin-
istration in the left nostril using a micropipette. Six doses were administered to ensure suffi-
cient dosing was achieved in the limited available sample. The post-treatment NPD
measurement was then recorded 48 hours after the last dose of eluforsen. In the further NPD
experiments, mice also received six IN doses of test item EOD (eluforsen, scrambled control,
or saline [five administrations at 60-second intervals to a total of 10 μL, 40 μg/dose]). This
experiment consisted of two baseline NPD measurements at days 1 and 7, and a post-treat-
ment NPD measurement at day 21 (24 hours after the last dose).
Statistical analysis
Data and statistics were analyzed using Graphpad Prism 6 and 7 (Graphpad Software, Inc.,
San Diego, CA, USA). All data were normally distributed. For in vitro experiments and initial
NPD experiments, Student’s t-test was used for comparisons between two groups; compari-
sons involving more than two groups were made using one-way analysis of variance using the
appropriate post hoc tests, as detailed in the figure legends. The repeated measures data from
the saliva secretion assay were analyzed using analysis of covariance (ANCOVA) and the gen-
eral linear model function in SAS (SAS, version 9) with the effect of baseline (pre-treatment
measurement) and repeated measures as covariates. For further NPD experiments, the effect
of treatment with eluforsen on ΔVTE total-Cl�was compared with the effect of treatment with
scrambled control or saline, while taking into account the baseline (pre-treatment) ΔVTE total-
Cl�values. For this purpose, ANCOVA was again used to compare treatment effects at post-
treatment NPD by only taking NPD baseline 2 (at day 7) into account as a covariate using the
general linear model in SAS (SAS, version 9). Differences were considered statistically signifi-
cant at p< 0.05.
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Results
Eluforsen restores CFTR activity in vitro as measured by chloride efflux
The in vitro effect of eluforsen on chloride efflux was assessed using MQAE, a fluorescent mol-
ecule that is quenched by chloride ions and is therefore used as a measure of intracellular chlo-
ride concentration. The effect of eluforsen was compared with that of the CF4–CF6 duplex or
CF4 alone. Eluforsen has the same sequence and 2’-O-methyl modifications as CF4, and phos-
phorothioate modifications were introduced to promote uptake by cells in vivo (see eluforsen
uptake below). Forskolin is used to stimulate CFTR-mediated chloride efflux. Using the
MQAE chloride efflux assay, it was shown that the level of chloride efflux in CFPAC-1 cells
was similar after treatment with the CF4–CF6 duplex or CF4 alone (Fig 1A), confirming that
CF4 is the active component of the duplex and sufficient for restoration of CFTR-mediated
chloride efflux. Eluforsen-induced increases in chloride efflux rates were slightly smaller than
those observed for CF4 and CF4–CF6 (eluforsen: 100% versus CF4–CF6: 120% versus CF4:
124%), suggesting a small impact of the phosphorothioate modifications on the function of
eluforsen. Nonetheless, eluforsen was shown to significantly increase chloride efflux compared
with scrambled control and untreated cells (Fig 1B), indicating that eluforsen also restores
CFTR-mediated chloride efflux.
Functional repair of CFTR by eluforsen was further assessed by measuring chloride conduc-
tance in HBE cells grown in ALI to mimic the situation in the lung. Compounds, such as elufor-
sen, were added to the medium to enable gymnotic uptake by the cells. Isc responses of HBE
cells incubated with eluforsen or scrambled control were measured using the Ussing chamber
assay. In this assay, Isc is an indicator of net ion transport taking place across the epithelium. Pri-
mary HBE cultures were chosen to maximize clinical relevance. The data showed that incuba-
tion of HBE cells grown in ALI culture with eluforsen resulted in an increase in Isc over time,
with a maximum effect observed after 14 days of incubation (S1A Fig); an incubation period of
14 days was therefore used in subsequent functional assessments of eluforsen in HBE cultures.
Eluforsen treatment significantly improved Isccompared with untreated cells and scrambled
control-treated cells (Fig 1C and 1D). The increase in Isc after eluforsen treatment was abolished
by CFTRinh-172, indicating that the restorative effect of eluforsen in primary HBE ALI cultures
was mediated by CFTR. This effect was observed in primary cells from multiple donors, and
was observed both in the presence and absence of a potentiator (S1B Fig).
To assess the dose–response effect of eluforsen, HBE cultures were treated with either elu-
forsen or scrambled control at concentrations ranging from 1 nM to 30 μM. The resulting
dose–response curve shows that eluforsen starts to be effective above 3 nM, with a maximum
effect at a concentration of 300 nM, and an EC50 of 28 ± 2.63 nM (Fig 1E). In contrast, the
scrambled control showed no effect until a concentration of 1,000 nM, with an EC50 of
1,002 ± 1.42 nM (p< 0.01 for EC50 versus eluforsen).
Eluforsen demonstrated intracellular presence following orotracheal
administration
Assessment of lung sections from WT mice using confocal microscopy indicated that the Cy5
signal of Cy5-labeled eluforsen, but not CF4, could be detected in the airway epithelium 4 days
after OT administration (Fig 2A). This finding suggests the phosphorothioate modifications
improved the cellular uptake of Cy5-labeled eluforsen compared with (non-phosphorothioate-
modified) Cy5-labeled CF4. In addition to the in vivo assessment of eluforsen, confocal
microscopy of primary homozygous p.Phe508del-CFTR HBE cells incubated with eluforsen in
vitro showed that Cy5-labeled eluforsen accumulated over a period of 4 weeks (Fig 2B).
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Biodistribution of eluforsen in vivo
To assess eluforsen uptake and accumulation in vivo, Cy5-labeled eluforsen was administered
OT and Cy5 signal was visualized over time. At 24 hours, Cy5 signal was detected in the epi-
thelial cells lining the airway lumen and in macrophages, and over time the signal decreased.
At later time points, the majority of the Cy5 signal was detected in macrophages. HPLC analy-
sis indicated that the Cy5 signal originated primarily from intact Cy5-labeled eluforsen (S2
Fig). In treated WT mice, Cy5-labeled eluforsen could be detected in post-mortem sections up
to 14 days after OT administration (Fig 3A). In vivo imaging data of IRDye800-labeled elufor-
sen in nude mice confirmed uptake by the airway epithelium and subsequent biodistribution
to extrapulmonary organs including the liver, kidney, spleen, and gastrointestinal tract (Fig 3B
and S4 Fig). No Cy5 could be detected after 24 hours in untreated mice that received Cy5 only.
Unlabeled eluforsen was measurable in blood 30 minutes after OT administration in both WT
and F508del-CFTR mice (S3 Fig) using hybridization HPLC. Moreover, unlabeled eluforsen
was also detected in the liver, kidney, and salivary glands after airway delivery (S3 Fig). In addi-
tion visualization of unlabeled eluforsen using in situ hybridization showed that eluforsen is
present in the bronchi-epithelium, septa of the alveoli, and macrophages (S3 Fig).
Eluforsen restores CFTR-mediated saliva secretion in F508del-CFTR mice
As in the sweat glands of patients with CF, the salivary glands of F508del-CFTR mice fail to
respond to β-adrenergic stimulation [35,36]. Therefore, saliva secretion resulting from β-
adrenergic stimulation may be used as a measure of CFTR function. Firstly, uptake of elufor-
sen by the salivary gland after OT administration was confirmed using hybridization HPLC
(S3B Fig). Saliva measurements indicated a significant increase in CFTR-mediated saliva secre-
tion after two doses of eluforsen in female F508del-CFTR mice compared with pre-treatment
levels and saline control (p< 0.0001), but no difference was detected in male mice (Fig 4). In
female F508del-CFTR mice, two to six doses of eluforsen strongly increased CFTR-mediated
saliva secretion. The effect of eluforsen persisted for up to 13 days after dosing, and was not
significantly different from saline-treated mice after 22 days (Fig 4). The percent change from
baseline saliva secretion as assessed a week prior to treatment is attached in (S6 Fig).
Eluforsen normalizes NPD in F508del-CFTR mice
The bioelectric abnormalities observed in NPD measurements in patients with CF and p.
Phe508del mutation and in F508del-CFTR mice are very similar, with both showing a large
inhibition of NPD in the presence of amiloride (sodium channel inhibitor), and little or no
change in response to zero luminal chloride [37]. Treatment with six IN administrations of
eluforsen over two weeks in 129/FVB Cftrtm1EUR mice (n = 18) resulted in significant
Fig 1. Eluforsen increases chloride efflux in CFPAC-1 cells and restores CFTR function in p.Phe508del CF HBE cells. (A) CFPAC-1 cells transfected
with CF4–CF6 duplex or CF4 alone exhibited a slightly higher increase in fluorescence compared with eluforsen-transfected cells (�p< 0.05, n = 4). Mean of
values relative to eluforsen ± SEM are shown; differences between treatments were compared by one-way ANOVA with Tukey post hoc test. (B) CFPAC-1
cells transfected with eluforsen exhibited a significantly higher chloride efflux rate (as monitored by MQAE quenching) than untreated cells or negative
control oligonucleotide-transfected cells (�p< 0.05, n = 10). Mean of values relative to eluforsen ± SEM are shown; differences between treatments were
compared by one-way ANOVA with Tukey post hoc test. (C) Representative Isc traces of isoproterenol-stimulated HBE cultures that were untreated, treated
with eluforsen, or treated with scrambled oligonucleotide. (D) CFTR-specific Isc was significantly increased upon eluforsen treatment compared with
untreated HBE cultures (���p = 0.0007, n = 20 for untreated, n = 22 for eluforsen) and scrambled control-treated cultures (�p = 0.01, n = 24). Bars show
mean ± SEM; differences between treatments were compared by one-way ANOVA with Tukey post hoc test. (E) Dose–response curves of HBE cells treated
with eluforsen and scrambled control. The maximum effect of eluforsen is reached at a concentration of 300 nM, with an EC50 of 28 ± 2.63 nM. The
scrambled control-treated cultures also showed a modest response to treatment at a significantly higher concentration (EC50 1,002 ± 1.42 nM, p< 0.01,
n = 70 for eluforsen and n = 40 for scrambled control). Dots show mean ± SEM; the differences between the EC50s of the dose responses was compared by
Student’s t-test.
https://doi.org/10.1371/journal.pone.0219182.g001
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improvements in the increase in total VTE differences (ΔVTE) after perfusion with a zero-chlo-
ride buffer containing forskolin (ΔVTE total-Cl-; p = 0.0005) (Fig 5A and 5B). This effect was not
observed when only three IN administrations over one week were received (n = 5 mice; S5A
Fig). The effect of eluforsen on ΔVTE total-Cl- diminished 10 days after receiving the last of six
IN doses (n = 6 mice; S5B Fig). These data confirm the significant improvement in CFTR func-
tion in homozygous F508del-CFTR mice with eluforsen treatment. Due to the relatively high
background ΔVTE total-Cl- value in 129/FVB Cftr
tm1EUR compared with their WT littermates,
and preliminary data showing lower background ΔVTE total-Cl�in B6.129S6-Cftr
tm1Kth/J mice,28
the NPD assay was also carried out in B6.129S6-Cftrtm1Kth/J mice. These mice were treated
with IN eluforsen as well as saline and scrambled control to further verify the treatment effect.
Fig 2. Cy5-labeled eluforsen is visualized in the airway epithelial layer after OT administration. (A) Representative confocal
images of lung paraffin sections of wild-type mice that received daily OT administration of Cy5 (control), Cy5-labeled CF4, or
Cy5-labeled eluforsen (10 mg/kg; equimolar dose) for 3 consecutive days and were killed on day 4. Nuclei were stained with DAPI
(shown in blue). (B) Representative confocal images of HBE cultures treated with Cy5-labeled eluforsen (shown in red) stained for the
nucleus (Hoechst, blue) and F-actin (Alexa Fluor 488-phalloidin, green).
https://doi.org/10.1371/journal.pone.0219182.g002
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As shown in the 129/FVB Cftrtm1EUR mice, treatment with eluforsen significantly improved
the CFTR-mediated Cl�conductance compared with saline (p = 0.015) or scrambled controls
(p = 0.001) (Fig 5C) in B6.129S6-Cftrtm1Kth/J mice. There was no effect of gender observed on
the NPD outcome parameters for either mouse strain.
Discussion
This study shows that eluforsen is a bioavailable RNA oligonucleotide therapy that results in
functional CFTR in p.Phe508del-CFTR-mediated CF in in vitro and in vivo models. In two in
vitro models using two different assays, eluforsen restores chloride conductance. The first
model described in this report show that eluforsen significantly improves CFTR-mediated
chloride efflux compared with untreated and control-treated CFPAC-1 cells. Chloride efflux
assays are frequently used to verify functional CFTR with pharmacologic treatment [38]. How-
ever, CFPAC-1 cells show a very low level of CFTR expression [39–41], and thus may not accu-
rately reflect the level of effect that may be achieved in lung epithelium. Therefore, the effect of
eluforsen on CFTR activity in differentiated primary p.Phe508del HBE cell cultures, grown in
Fig 3. In vivo imaging and post-mortem detection demonstrate systemic exposure after OT administration of
labeled eluforsen. (A) Representative confocal images of lung paraffin sections of wild-type (WT) mice following a
single OT administration of 10 mg/kg Cy5-labeled eluforsen (shown in red) and killed after 24 hours, 48 hours, 3 days,
7 days, and 14 days. The cell nucleus was stained with DAPI (shown in blue). Macrophages accumulate the Cy5-labeled
eluforsen and are visible as highly fluorescent spherical cells (as indicated with the yellow arrows). (B) (i)
Representative in vivo images at several time points showing the IRDye800 (CW800) signal from IRDye800-labeled
eluforsen in green. Systemic exposure could be detected at 1 hour after administration. (ii) Mice were killed after 7
days and representative in situ images demonstrate a strong IRDye800 signal in the lungs. (iii) High-resolution post-
mortem scans of organs from all animals show extrapulmonary distribution of eluforsen. Controls include a mouse
that received an equimolar dose or IRDye800 alone (CW800) or unlabeled eluforsen. Mouse M1 shown (see S4 Fig for
additional animals).
https://doi.org/10.1371/journal.pone.0219182.g003
Fig 4. Eluforsen restores CFTR-mediated saliva secretion in female F508del-CFTR mice. CFTR-mediated saliva secretion in eluforsen-treated
F508del-CFTR mice before treatment (at day 1) and 24 hours after one (day 8), two (day 10), four (day 14), and six (days 18, 22, 30, 39, 45) OT
administrations of saline or eluforsen (10 mg/kg), corrected for body weight (μg saliva/g body weight). The symbols and error bars indicate the mean
and SEM. The solid line represents the mean CFTR-mediated saliva secretion corrected for body weight in eluforsen-treated (female n = 9; male n = 10)
mice and the dashed line represents the saline-treated (female n = 9; male n = 8) mice. Two to six OT administrations of eluforsen significantly improve
CFTR-mediated salivary secretion in female F508del-CFTR mice compared with saline-treated controls. CFTR-mediated saliva secretion gradually
returned to pre-treatment levels at day 39 (22 days after the sixth dose), confirming washout of eluforsen. Treatment groups were compared using
ANCOVA (general linear model), using the effect of baseline (pre-treatment measurement) and repeated measures as covariates. ����p< 0.0001,
��p< 0.01, �p< 0.05.
https://doi.org/10.1371/journal.pone.0219182.g004
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ALI to mimic the lung epithelium, was also tested. Called the Ussing chamber, this model also
allows for measurement of chloride currents, which reflect CFTR activity. While a transfection
agent was used to enhance intracellular uptake of eluforsen in CFPAC-1 cells, eluforsen was
taken up by p.Phe508del-CFTR HBE cells after continued exposure in the medium. Exposure
time to eluforsen correlated with a significant improvement in CFTR activity as measured by
increased Isc responses in the Ussing chamber assay of p.Phe508del-CFTR HBE cells compared
Fig 5. Eluforsen restores NPD in two different strains of F508del-CFTR mice. (A) Representative NPD traces in WT littermates, untreated 129/FVB
Cftrtm1EUR mice, and eluforsen-treated 129/FVB Cftrtm1EUR mice. (B) ΔVTE total-Cl- obtained from NPD recordings in 129/FVB Cftr
tm1EUR mice at pre-
treatment and after six intranasal doses (EOD) of 40 μg eluforsen (open bars; n = 18), and in untreated WT littermates (black bars; n = 6). Eluforsen
significantly increases CFTR-mediated chloride permeability compared with pre-treatment levels, and to approximately 80% of WT levels. Bars show
mean ± SEM. ΔVTE total-Cl- values in mice before and after eluforsen treatment were compared by paired t-test (���p = 0.0001); the differences in ΔVTE total-
Cl- values between eluforsen-treated and WT littermates were compared by unpaired t-test (ns: non-significant). (C) In B6.129S6-Cftr
tm1Kth/J mice, the
ΔVTE total-Cl�measurements at baseline were similar between treatment groups, but less negative compared with 129/FVB Cftr
tm1EUR mice. At 24 hours
post-treatment, eluforsen-treated mice (n = 10) had significantly improved ΔVTE total-Cl�(more negative) compared with both saline (n = 9) and the
scrambled control (n = 10). Bars show mean ± SEM. The effect of eluforsen treatment on ΔVTE total-Cl�values was compared with the ANCOVA control
groups using the pre-treatment NPD value (��p = 0.015, ���p = 0.0001).
https://doi.org/10.1371/journal.pone.0219182.g005
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with scrambled control-treated p.Phe508del-CFTR HBE cells. Although the scrambled control
appears to have a small but non-significant effect on Isc at higher concentrations, the EC50 of
eluforsen is significantly lower than that of the scrambled control. The increased Isc seen with
the scrambled oligonucleotide could be attributed to non-sequence-specific effects, for exam-
ple caused by the phosphorothioate modifications, frequently observed with control oligonu-
cleotides at very high concentrations [42]. Given the origin and expansion of primary HBE cell
lines, it is challenging to compare absolute results either from experiment to experiment or
from p.Phe508del-CFTR HBE to WT HBE cells. Nonetheless, these two in vitro models dem-
onstrate transmembrane chloride conductance following exposure to eluforsen. In addition,
OT administration of eluforsen achieved good uptake and persistence of this oligonucleotide
in pulmonary epithelial cells; extrapulmonary distribution of eluforsen was also observed after
OT administration.
The murine model of homozygous p.Phe508del-CFTR-mediated CF [30,31] has previously
been described as excellently suited for studying the pharmacology of therapeutic agents
intended to restore CFTR function [34,43–45]. Moreover, the RNA at the Phe508del site in
this murine model is 100% homologous to the human RNA at this same site [30–32]. As such,
this model was considered suitable to test eluforsen, an antisense oligonucleotide synthesized
following the human Phe508del site RNA sequence.
The respiratory route of administration was chosen as a way to target the large surface area
of the airway epithelium where CFTR is densely expressed, as well as to avoid the first pass
effect in the liver that is well recognized with antisense oligonucleotide therapies administered
systemically. There are barriers to uptake of unmodified oligonucleotides or small double-
stranded RNA sequences by the airway epithelium, and subsequent distribution to other
organs [46]. However, the results presented here demonstrate rapid uptake by airway epithe-
lium of both fluorescently labeled and unlabeled eluforsen after OT administration, and is dis-
tributed via systemic circulation to extrapulmonary organs (mostly the liver and kidney, but
also detected in the gastrointestinal tract and salivary glands). Importantly, OT administration
simulates inhalation, which is the intended clinical route of eluforsen administration. More-
over, Cy5-labeled eluforsen levels remain stable in the lungs for at least 14 days after OT
administration. This prolonged in vivo stability of eluforsen in the target tissue is important
considering the expected short half-life of the CFTR protein and mRNA in epithelial cells [47–
49]. Importantly, these data show that the lung is also a portal of entry for systemic delivery of
eluforsen to other extrapulmonary organs that are affected by CF. The results of the present
study suggest that extrapulmonary distribution of eluforsen to target organs is achieved after
OT administration. Uptake by alveolar macrophages is also noted, consistent with their pri-
mary function of clearing foreign debris from the lungs.
We also investigated the pharmacodynamic effects of eluforsen in vivo. Clinically relevant
assays were used to assess the effect of eluforsen on CFTR function in two different epithelial
tissues: the salivary glands and nasal epithelium. The saliva secretion assay is the murine equiv-
alent of the sweat test that is used as a primary or surrogate endpoint in human clinical trials
[34,36]. The failure of salivary glands in F508del-CFTR mice to respond to β-adrenergic stimu-
lation corresponds to the failure of sweat glands in patients with CF to secrete fluid in response
to β-adrenergic stimulation [50]. OT delivery of two to six doses of eluforsen restored CFTR-
mediated saliva secretion in a dose-dependent manner in female p F508del-CFTR mice. This
effect was observed up to 13 days after the last dose, and was not significantly different from
pre-treatment after 22 days. No effect of eluforsen on CFTR-mediated salivary production was
observed in male F508del-CFTR mice. However, this is not surprising considering previously
reported differences in the responses of male and female mice in the saliva secretion assay, sug-
gested to be related to morphologic, chemical/hormonal, and physiologic variations between
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male and female salivary glands [36]. In addition, it was noted that in the saliva secretion assay
study, the saline-treated female mice also showed increased saliva secretion over time. This
increased secretion is attributed to the effect of the anesthetics (isoflurane and multiple admin-
istrations of atropine and isoproterenol within relatively short time intervals). Since the saliva
secretion levels in female eluforsen-treated mice increased much earlier than levels in saline-
treated mice, the early improvement is considered to be an eluforsen-specific effect.
NPD is highly dependent on functioning CFTR. Since the early 1980s, measurement of
NPD has been used extensively for the diagnosis of CF as the measurements are sensitively
and specifically different when there is no functioning CFTR [51]. In addition to use as a diag-
nostic tool specific to patients with CF, NPD is also currently being used as a surrogate marker
of CFTR activity in several clinical trials [22–24,51]. Using this measure of chloride conduc-
tance in mutant F508del-CFTR (129/FVB Cftrtm1EUR) mice and B6.129S6-Cftrtm1Kth/J mice
compared with their respective WT mice, it was found that IN administration of eluforsen
restores chloride conductance in F508del-CFTR mice. This effect was dose-dependent; a mini-
mum of six doses was needed to achieve functional correction. After six IN doses, a washout of
eluforsen was observed with NPD returning to pre-treatment levels after 10 days. This mirrors
the findings of a phenotypic reversal of p.Phe508del previously reported by Zamecnik et al. in
cultured cells [21], and is in agreement with the reversibility of increased saliva production
observed in the saliva secretion assay. These data further support the hypothesis of eluforsen-
mediated functional restoration of p.Phe508del-CFTR.
In summary, the results presented in this report demonstrate that eluforsen, a single-
stranded, chemically modified RNA oligonucleotide, improved CFTR function in two vitro
models and in two in vivo models using mice with the p.Phe508del-CFTR genotype. These
encouraging preclinical data served as the foundation for two human clinical trials of eluforsen
in patients with p.Phe508del-CFTR-mediated CF (NCT02564354 and NCT02532764). For one
of these two studies, NPD was measured in patients before and after intranasal administration
of eluforsen and showed restoration of CFTR function, further confirming the murine NPD
data described here [52]. Moreover, data from a phase 1b dose escalation study demonstrated
an improvement in CFQ-R RSS, a relevant measure of clinical benefit in CF patients, after elu-
forsen treatment [53].
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S1 Fig. Uptake of eluforsen by HBE cells over time results in improved CFTR function. (A)
Isc measurements of HBE cultures showed improved chloride permeation over time, with opti-
mal response after 2 weeks of treatment (n = 3). The decrease in Isc after 4 weeks of treatment
may indicate deterioration in cell viability, corresponding to the irregular staining of the HBE
cells seen by confocal microscopy in Fig 1B. (B) Isc measurements of HBE cultures from two
additional donors showing similar increases in current in cells treated with eluforsen, but not
in cells treated with scrambled control. This was observed both with and without concomitant
potentiator (genistein) treatment (n =�4. Bars show mean ± SEM).
(TIFF)
S2 Fig. Cy5 signal detected in lung tissue corresponds to Cy5 bound to eluforsen. Total Cy5
signal was detected using hybridization HPLC. Percentages of Cy5-labeled eluforsen (intact),
Cy5-labeled metabolites of eluforsen (truncated eluforsen with Cy5 label), and free Cy5 as part
of the total Cy5 signal in lung tissue at 24 hours, 7 days, and 14 days after OT administration
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of Cy5-labeled eluforsen. The exact molecular entities of the truncated eluforsen with Cy5
label could not be identified with the current method, but were expected to consist of eluforsen
without 1 to 3 nucleotides from the ‘3 end. The bar represents the mean percentage of each
analyte, with n = 2 mice per time point. The majority (~75%) of the Cy5 signal is from intact
Cy5-labeled eluforsen 24 hours and 7 and 14 days after OT administration. The percentage of
Cy5 corresponding to truncated eluforsen was increased at 14 days after OT administration.
At all time points measured, the amount of free Cy5 was very low (< 5%), indicating that the
Cy5 signal detected in the lung corresponds to eluforsen-bound Cy5.
(TIFF)
S3 Fig. Biodistribution of eluforsen in WT mice after OT administration. WT mice
received a single OT administration of eluforsen (10 mg/kg), which resulted in rapid absorp-
tion by the lung, systemic exposure to blood (A), and rapid biodistribution to the liver, kidney,
and salivary gland. (B) Hybridization HPLC shows that eluforsen concentration in all organs
stabilizes within the first 24 hours, and remains stable for a week. The maximum concentration
in serum is reached 2–4 hours after OT administration, and remains stable near lower detec-
tion levels after 24 hours (n = 3 mice per time point). (C) In situ hybridization shows that elu-
forsen (brown, left side) was detected in the bronchi-epithelium, septa of the alveoli, and
macrophages (as indicated with arrows) of WT mice 24 hours after a single OT administration
of eluforsen. No eluforsen was detected in saline-treated WT mice (right side).
(TIF)
S4 Fig. In vivo imaging of IRDye800-labeled eluforsen in nude mice. Nude mice (M2 and
M3) were dosed via OT administration with IRDye800-labeled eluforsen, and absorption by
the airway epithelium and biodistribution to extrapulmonary organs were assessed by in vivo
imaging and post-mortem detection. Several time points after OT administration show the
IRDye800 signal in green. Systemic exposure could be detected at 1 hour after administration.
Mice were killed after 7 days, and representative in situ images demonstrate a strong
IRDye800 signal in the lungs. The signal from IRDye800 (CW800) alone disappeared 6 hours
after dosing, suggesting a different biodistribution profile. No signal was detected in the
mouse treated with unlabeled eluforsen.
(TIF)
S5 Fig. Effect of eluforsen on CFTR-mediated chloride permeability in 129/FVB
Cftrtm1EUR mice. (A) Eluforsen increased CFTR-mediated chloride permeability in 129/FVB
Cftrtm1EUR mice after six (n = 18; in 14 days), but not three (n = 5; in 7 days) intranasal doses
(40 μg/dose) EOD as shown by the ΔVTE total-Cl- parameters. Mean ± SEM shown. ΔVTE total-
Cl- values in F508del-CFTR mice before and after eluforsen treatment were compared by
paired t-test (���p = 0.0005). ΔVTE total-Cl- values between eluforsen-treated F508del-CFTR
mice and WT littermates were compared by unpaired t-test (ns). (B) Washout effect on ΔVTE
total-Cl- in post-treatment (n = 18), 10 days post-treatment (n = 6), and 17 days post-treatment
(n = 2) in 129/FVB Cftrtm1EUR mice, showing return to pre-treatment levels within 10 days.
Bars show mean ± SEM. ΔVTE parameters before and after eluforsen treatment were compared
by paired t-test (���p = 0.0005).
(TIFF)
S6 Fig. Eluforsen restores CFTR-mediated saliva secretion in female F508del-CFTR mice.
The percent change from baseline (day 1) CFTR-mediated saliva secretion in eluforsen-treated
F508del-CFTR mice after 24 hours and after one (day 8), two (day 10), four (day 14), and six
(days 18, 22, 30, 39, 45) OT administrations of saline or eluforsen (10 mg/kg). The symbols
and error bars indicate the mean and SEM. The solid line represents the mean percentage
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(female n = 9; male n = 10) mice and the dashed line represents the saline-treated (female
n = 9; male n = 8) mice. Treatment groups were compared using ANCOVA (general linear
model), using the effect of baseline (pre-treatment measurement) and repeated measures as
covariates. ����p< 0.0001, ��p< 0.01, �p< 0.05.
(TIF)
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